All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Sentynl Therapeutics and Fortress Biotech receive FDA approval for Zycubo targeting ATP7A protein for Menkes disease
Protein therapy, metabolic, copper replacement therapy, Menkes disease, rare pediatric disease - Read more

Bio Usawa receives Ghana FDA approval for BioUcenta (ranibizumab) biosimilar targeting diabetic macular edema and retinopathy
Antibody, ophthalmology, monoclonal antibody, diabetic macular edema, age-related macular degeneration, biosimilar - Read more

THE GOOD
Business Development & Partnerships

Etienna Bio, UMass Chan Medical School partner on exclusive worldwide license for adipose-derived regenerative platform
Licensing deal, regenerative medicine, cell therapy, autologous therapy - Read more

Nxera Pharma, Centessa Pharmaceuticals achieve milestone for orexin receptor agonist ORX142, $3.6M payment
Research collaboration, neurological, milestone payments, small molecule - Read more

ESTEVE to acquire TerSera Therapeutics' infusion specialty therapies business unit expanding U.S. presence
Acquisition, specialty infusion therapies, pain management, rare disease - Read more

Illumina, AstraZeneca, Merck & Co., Eli Lilly partner on Billion Cell Atlas for AI drug discovery
Research collaboration, AI/ML, drug discovery, oncology, neurological, rare disease - Read more

Bayer, Attralus partnership acquires cardiac amyloidosis imaging agents AT-01, AT-05 for undisclosed sum
Acquisition, rare disease, diagnostics, molecular imaging - Read more

Novartis, Zonsen PepLib Biotech partner on peptide-based radiopharmaceutical asset, $50M upfront plus milestones
Licensing deal, radiopharmaceuticals, peptide therapeutics, milestone payments, oncology - Read more

Ro, Amgen partner on research analyzing insurance coverage barriers for GLP-1 obesity treatments
Research collaboration, obesity, real-world evidence, data analytics - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Immunofoco presents Ph1/Ph2a data for IMC002 CAR-T therapy targeting advanced gastric and gastroesophageal junction cancers
Cell therapy, cancer, CAR-T, gastric cancer, CLDN18.2 target - Read more

ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept) shows positive Ph2/Ph3 results in non-small cell lung cancer
Protein therapy, cancer, cytokine therapy, non-small cell lung cancer, combination therapy, checkpoint inhibitors - Read more

THE GOOD
Earnings & Finances

Ionis Pharmaceuticals doubles Tryngolza peak sales projection to $2B for severe hypertriglyceridemia indication
Antisense oligonucleotide, cardiovascular, financial, revenue impact - Read more

THE GOOD
Fundraises

Nuclera extends Series C to $87M for antibody engineering platform development
Protein engineering, antibody, platform technology, AI-driven - Read more

Find Therapeutics raises $10M Series A extension for multiple sclerosis drug development
Neurological, peptide, multiple sclerosis, clinical-stage - Read more

Proxima raises $80M seed, AI-powered proximity-based therapeutics for undruggable targets
AI/ML platform, small molecule, oncology, immunology, protein design, platform technology - Read more

Converge Bio raises $25M Series A, AI platform for drug discovery
AI/ML platform, drug discovery, platform technology, oncology, neurological, autoimmune - Read more

THE GOOD
Investments

AbbVie commits $100B US R&D investment over 10 years, wins tariff and pricing exemptions
Biologic, autoimmune, strategic, major transaction, operational - Read more

J&J to create 500 jobs with second North Carolina manufacturing plant in $55B U.S. investment plan
Biologics, oncology, neurological, operational, major investment, manufacturing expansion - Read more

THE GOOD
Mergers & Acquisitions

AstraZeneca acquires Modella AI to integrate multimodal foundation models into its oncology R&D operations
Antibody-drug conjugate, oncology, strategic, major transaction - Read more

XTL Biopharmaceuticals acquires 85% of Beyond Air's NeuroNOS subsidiary, entering autism therapeutics market
Disease-modifying therapeutic, neurological, strategic, major transaction - Read more

Pretzel Therapeutics acquires Rome Therapeutics as subsidiary after Rome winds down operations due to market challenges
Reverse transcriptase inhibitor, autoimmune, strategic, major transaction - Read more

THE GOOD
Politics & Policy

US Senate committee unveils 22 biotech regulatory reform proposals to counter China's growing innovation threat
Regulatory, strategic, competitive, biotech innovation - Read more

THE GOOD
Product Launches

Cellistic launches three new iPSC-based platforms Echo-T, Echo-Cardio, and Echo-Endothelial for immuno-oncology therapies
Cell therapy, oncology, strategic, operational - Read more

THE GOOD
Regulatory

UK clinical trial applications rise 9% as MHRA plans faster approval reforms for 2025
Regulatory, strategic, operational, investment - Read more

FDA requests removal of suicide warnings from Novo Nordisk and Eli Lilly GLP-1 drug labels
GLP-1 receptor agonist, metabolic disease, regulatory, operational - Read more

THE GOOD
Strategic Plans

Merck & Co. targets $70B revenues by mid-2030s, double Keytruda's peak sales estimates
Monoclonal antibody, oncology, strategic, major transaction, revenue impact - Read more

Novo Nordisk CEO outlines refocused strategy on diabetes, obesity after challenging 2025 performance
GLP-1 agonist, diabetes, strategic, operational - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Approvals & Labels

FDA extends Travere Therapeutics' Filspari (sparsentan) review for focal segmental glomerulosclerosis by three months
Small molecule, kidney disease, dual endothelin angiotensin receptor antagonist, focal segmental glomerulosclerosis, proteinuria reduction - Read more

THE BAD
Layoffs

Lyra Therapeutics suspends LYR-210 rhinosinusitis development, lays off all 28 employees amid strategic review
Drug delivery device, rhinosinusitis, operational, cost reduction - Read more

Sonoma Biotherapeutics reduces workforce across Seattle and South San Francisco offices after recent CEO transition
Cell therapy, autoimmune, operational, cost reduction - Read more [Paywall]

THE BAD
Politics & Policy

NIH heart, lung and blood director Gary Gibbons retires, adding to extensive leadership turnover
Cardiovascular, organizational, leadership transition, institutional - Read more

THE BAD
Regulatory

AbbVie, Amgen, Eli Lilly urge FDA to update outdated post-approval manufacturing change rules to reduce regulatory burdens
Monoclonal antibody, biologics manufacturing, operational, strategic - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here